Business
Initiation Of Phase I/IIA Stu
Initiation Of Phase I/IIA Stu.
About this update from Immupharma Plc
[{"type":"text","content":"\n RNS Number : 1612M Immupharma PLC 19 May 2010 \n \n\nFOR IMMEDIATE RELEASE 19 May 2010\n \nIMMUPHARMA RECEIVES APPROVAL FOR\n INITIATION OF PHASE I/IIA STUDIES IN CANCER \n\n \nImmuPharma PLC (LSE:IMM), (\"ImmuPharma\" or the \"Company\"), the specialist drug discovery and development company, is pleased to announce that it received an Investigational New Drug (IND) approval from AFSSAPS, Agence Francaise de Securite Sanitaire des Produits de Sante, for a Phase I/IIa study in patients of IPP-204106, its anti-cancer compound with a novel and promising mechanism of action. The first patients are expected to be dosed within the next few weeks. \n \n \nDr Robert Zimmer, President and Chief Scientific Officer, said: \"We are delighted with the approval of our IND application, and are excited to begin Phase I in patients for IPP-204106 in the next few weeks. Importantly, our strong financial position means we are well-placed to take the development programme forward.\"\n \n \nFor further information please contact:\n \nImmuPharma PLC\nRobert Zimmer, President & Chief Scientific Officer +33 3 8932 7650\nRichard Warr, Chairman ...